Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
Takeaways: Felix is positioning itself as the price‑breaker in Canada’s GLP‑1 obesity market, using cheaper semaglutide (as generics arrive) to tackle the main dropout driver and convert strong ...
Takeaways: This authorization makes iStatis the first rapid point‑of‑care HBsAg test cleared in both Canada and North America, giving frontline providers a 15‑minute to...
Takeaways: BC’s decision makes REVESTIVE a province‑funded option for both adult and pediatric Short Bowel Syndrome patients who depend on parenteral support, align...
Takeaways: CELYSTRA is being set up as a dedicated Canadian “importer–operator” for advanced rare‑disease drugs, starting with RNA therapeutics. It’s led by senior ex‑big‑pha...
Takeaways: Kisunla adds a new money‑maker for Lilly in Canada, but real sales will depend on how fast the system can diagnose patients early and pay for the drug. Because testing and speci...
Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
Takeaways Bepirovirsen’s Canada filing signals a coming shift in the hepatitis B market from lifelong viral suppression to time‑limited “functional cure” regimens, which could reshape how p...
Takeaways: Pharmascience Canada has launched pms–Dolutegravir, becoming the only Canadian generic manufacturer with Health Canada authorization for dolutegravir tablets and adding a key HIV back...
